甲磺酸艾立布林治疗晚期乳腺癌的研究进展

Research Progress of Eribulin Mesylate in Treatment of Advanced Breast Cancer

晚期乳腺癌患者的生存率较低,且易产生耐药性,尤其是紫杉类药物治疗失败的患者,急需选择其他治疗方案以延长患者的生存期。对于晚期乳腺癌的治疗方式,化疗仍是优先选择,甲磺酸艾立布林是非紫杉类微管动力抑制剂,其作用机制区别于其他微管动力抑制剂(如紫杉类和长春碱类),单用或与其他化疗药物联合使用均具有较好的抗肿瘤作用,且不良反应少,目前已被批准用于既往接受过至少两种化疗方案(包括蒽环类和紫杉类)治疗的局部复发或转移性乳腺癌患者。

The survival rate of patients with advanced breast cancer is low,and the patients are prone to drug resistance,especially for patients with failure of taxanes,it is urgent to choose other treatment schemes to prolong their survival.Chemotherapy is still preferred for the treatment of advanced breast cancer.Eribulin mesylate is a non-taxane microtubule dynamics inhibitor,and its mechanism is distinct from other microtubule inhibiting agents such as taxanes and vinca alkaloids.Both alone or in combination with other chemotherapeutic drugs,eribulin mesylate has good anti-tumor effects and less adverse reactions,which has been approved for patients with locally recurrent or metastatic breast cancer after at least two lines of chemotherapy(including anthracyclines and taxanes).